Glaukos (NYSE:GKOS) Price Target Raised to $145.00 at Stifel Nicolaus

Glaukos (NYSE:GKOS - Free Report) had its price target lifted by Stifel Nicolaus from $130.00 to $145.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier's stock.

GKOS has been the subject of a number of other research reports. Wells Fargo & Company boosted their target price on Glaukos from $120.00 to $135.00 and gave the stock an overweight rating in a research report on Thursday, August 1st. StockNews.com downgraded shares of Glaukos from a hold rating to a sell rating in a research report on Friday. Morgan Stanley lifted their target price on shares of Glaukos from $100.00 to $120.00 and gave the stock an equal weight rating in a research report on Monday, July 15th. Citigroup cut Glaukos from a buy rating to a neutral rating and increased their price target for the company from $130.00 to $132.00 in a report on Wednesday, July 10th. Finally, Jefferies Financial Group raised Glaukos from a hold rating to a buy rating and lifted their price objective for the stock from $84.00 to $125.00 in a report on Monday, May 6th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $129.82.

Glaukos Stock Down 0.7 %

Shares of NYSE GKOS traded down $0.89 during midday trading on Tuesday, hitting $133.00. The stock had a trading volume of 481,592 shares, compared to its average volume of 586,187. The business's 50 day moving average is $122.67 and its 200-day moving average is $108.05. Glaukos has a 52 week low of $59.22 and a 52 week high of $136.60. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. The company has a market cap of $6.70 billion, a P/E ratio of -46.49 and a beta of 1.05.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). The business had revenue of $95.70 million for the quarter, compared to analysts' expectations of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The firm's quarterly revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.55) EPS. As a group, analysts predict that Glaukos will post -2.18 EPS for the current year.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,250 shares of the stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $121.39, for a total transaction of $273,127.50. Following the completion of the transaction, the chief operating officer now owns 101,845 shares of the company's stock, valued at approximately $12,362,964.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Marc Stapley sold 6,250 shares of the firm's stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now directly owns 34,076 shares in the company, valued at approximately $4,291,190.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 2,250 shares of the company's stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $121.39, for a total transaction of $273,127.50. Following the transaction, the chief operating officer now owns 101,845 shares in the company, valued at approximately $12,362,964.55. The disclosure for this sale can be found here. Insiders sold a total of 38,500 shares of company stock valued at $4,706,990 over the last three months. Corporate insiders own 6.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. National Bank of Canada FI acquired a new position in Glaukos during the 4th quarter worth approximately $46,000. Quadrant Capital Group LLC boosted its position in Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock worth $74,000 after purchasing an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. raised its position in shares of Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier's stock worth $140,000 after purchasing an additional 1,465 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier's stock worth $141,000 after buying an additional 486 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos during the 2nd quarter valued at about $187,000. Hedge funds and other institutional investors own 99.04% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.